GlassScriptPhysician profile
Lori A Mcintosh
NPI 1710956602
$2,353.71
in general payments reported to CMS, 2019-2025
25 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $298 · 2022: $195 · 2023: $241 · 2024: $914 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $542.70 | 2023-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $248.16 | 2021-2025 | Briviact, Fintepla |
| Lilly USA, LLC | $241.12 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $211.87 | 2021-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $181.74 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $150.29 | 2021-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $120.37 | 2025 | Ultomiris |
| Eisai INC. | $106.37 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $88.35 | 2024 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Genentech USA, INC. | $70.70 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $63.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $32.27 | 2024 | |
| Biogen, INC. | $27.38 | 2025 | Vumerity |
| Mallinckrodt Hospital Products INC. | $24.40 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $23.75 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.46 | 2022 | |
| Abbott Laboratories | $22.79 | 2025 | Infinity |
| Livanova USA, INC. | $21.29 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $18.62 | 2021 | |
| Pfizer INC. | $18.61 | 2023 | |
| Neurelis, INC. | $17.09 | 2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $15.54 | 2024 | Nuedexta |
| Biohaven Pharmaceuticals, INC. | $14.29 | 2021 | |
| Acorda Therapeutics, INC | $13.81 | 2024 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.